The three Rs

Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing

Retrieved on: 
Tuesday, April 16, 2024
Research, Animal Welfare, Medical Devices, Public Policy, Government, Biotechnology, Health, Pharmaceutical, General Health, Science, Corporation, Safety, Policy, Valo, AI, Animal, Pathology, Logica, Patient safety, AMAP, Patient, The three Rs, Multimedia, Non-governmental organization, Drug development, CRL, Drug discovery, Pharmaceutical industry

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it is launching its Alternative Methods Advancement Project (AMAP), an initiative dedicated to developing alternatives to reduce animal testing.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it is launching its Alternative Methods Advancement Project (AMAP), an initiative dedicated to developing alternatives to reduce animal testing.
  • This investment spans a portfolio of technology innovations, partnerships, and advocacy efforts to reduce the use of animal testing.
  • View the full release here: https://www.businesswire.com/news/home/20240416134140/en/
    Understanding that stakeholders across drug development must collaborate to pursue these advances, AMAP is comprised of Charles River experts in animal welfare, science, technology, operations, and advocacy.
  • AMAP focus is on three key pillars:
    Products & Services: Charles River is committed to innovating and expanding its portfolio to include more animal alternatives.

Instem Enables Clients to Leverage ICH S1B Weight of Evidence Guideline

Retrieved on: 
Thursday, January 25, 2024
Science, Software, Other Science, Biotechnology, Research, Health, Data Management, Technology, The three Rs, Database, Life, S1B, Workflow, Drug discovery, Woe, ICH, Organization, Guideline, Patient safety, Literature, Growth, Pharmaceutical industry

Instem, a leading provider of IT solutions and services to the global life sciences market, announced today that its latest in silico solution offering known as Advance™ is providing clients with a technology-enabled approach for assessing carcinogenicity based on the ICH S1B Weight of Evidence (WoE) Addendum .

Key Points: 
  • Instem, a leading provider of IT solutions and services to the global life sciences market, announced today that its latest in silico solution offering known as Advance™ is providing clients with a technology-enabled approach for assessing carcinogenicity based on the ICH S1B Weight of Evidence (WoE) Addendum .
  • The ICH S1B guideline has introduced a WoE approach to assess human carcinogenic potential of small molecule pharmaceuticals and determine whether a 2-year rat carcinogenicity study would add value.
  • Application of this integrated analysis supports the 3Rs principles, while promoting safe and ethical development of new small molecule pharmaceuticals.
  • Since that time, Instem’s team of in silico experts have been instrumental in driving forward a solution to support the S1B guideline.